WASHINGTON, DC—The CDC has launched the first national surveillance system to monitor adverse events in patients who receive blood transfusions.

The system, called the Hemovigilance Module, is part of CDC’s National Healthcare Safety Network (NHSN), an Internet-based surveillance system that allows healthcare-associated infection data to be tracked and analyzed, allowing CDC and healthcare facilities to maximize prevention efforts. The module was developed by CDC in collaboration withAABB, an international association representing organizations involved in transfusion and cellular therapies.

CDC is encouraging healthcare facilities across the country to enroll in this new surveillance system, which was designed to improve patient safety. “This is an important advance in monitoring the safety of transfusions for patients nationwide,” said Matthew J Kuehnert, MD, director of the CDC’s Office of Blood, Organ, and Other Tissue Safety, in a statement. “This system will enable healthcare facilities to better recognize blood transfusion-related adverse events so that they can improve the care of patients who have transfusions.”

Hospitals will submit data confidentially to CDC through the Hemovigilance Module. CDC will review the national data in collaboration with AABB and other partners to help identify ways to improve the safety of blood transfusion. Previously, transfusion-related events were monitored by facilities on their own. Now, hospitals that join the Hemovigilance Module will have access to standardized data analysis tools, as well as an opportunity to see how their data compare to other hospitals throughout the United States.

CDC is providing the module at no cost to hospitals and healthcare facilities. The agency also provides participating facilities with training and ongoing user support at no cost to the facilities.

back to March articles